tbuckley/cabot-search huggingface dataset:
Impact of internal mammary node inclusion in the radiation treatment volume on the outcomes of patients with breast cancer treated with locoregional radiation after six years of follow-up.
Authors: R. A. Olson, R. Woods, J. Lau, C. Speers, A. Lo, S. Tyldesley, L. Weir
Journal: Journal of Clinical Oncology (2011)

81 Background: There is ongoing controversy about radiotherapy (RT) to internal mammary nodes (IMNs). Proponents of IMN RT cite the survival benefit seen in postmastectomy RT trials that included IMNs. However, others point out that benefit cannot be definitively attributed to IMN inclusion, as other lymph node regions were included in the RT arms. The issue is important, as IMN RT potentially increases cardiac and respiratory morbidity. Methods: 2,413 women referred to a provincial RT program with newly diagnosed node positive, or T3/4N0 non-M1 invasive breast cancer, treated with a complete course of locoregional RT from 2001 to 2006, were retrospectively identified in a provincial database. IMN RT inclusion versus exclusion was determined through review of patient charts and RT treatment plans. Breast cancer-specific survival (BCSS), relapse-free survival (RFS), and overall survival (OS) were compared between the two groups using univariate and multivariable analyses. Results: Analyses were performed at a median follow-up of 6.2 years. 41.4% of the subjects received IMN RT. The 5-year BCSS for the IMN inclusion and exclusion group was 84.8% versus 82.9%, respectively (HR 0.93 [95% CI 0.76, 1.14]; p=.51); the 5-year RFS was 87.4% versus 86.9% (HR 0.993 [0.83, 1.19]; p=0.94); and the 5-year OS was 84.8% versus 82.9% (HR 0.84 [0.70, 1.01]; p=0.06). After controlling for potentially confounding variables, there was no significant difference in BCSS (HR 0.96 [0.78, 1.18], p=0.88), RFS (HR 1.02 [0.84, 1.22], p=0.87), or OS (HR 0.91 [0.76, 1.10]; p=0.35). Conclusions: After a median follow-up of 6.2 years, this population-based study shows no benefit from including IMNs in the locoregional RT volume after adjusting for other prognostic and treatment variables.
A Genomic Strategy To Refine Prognosis and Predict Response to Therapy in Chronic Lymphocytic Leukemia.
Authors: Daphne R. Friedman, J. Brice Weinberg, Anil Potti, Alicia D. Volkheimer, Karen M. Bond, Youwei Chen, Ning Jiang, Joseph O. Moore, Jon P. Gockerman, Louis F. Diehl, Carlos M. Decastro, Joseph R. Nevins
Journal: Blood (2007)
Voriconazole and Non-Melanoma Skin Cancer after Allogeneic HSCT: Results of a Prospective Dedicated Follow-up Program in 302 Patients
Authors: Maria Teresa Lupo-Stanghellini, Raffaella Greco, Andrea Angelo Assanelli, Tommaso Perini, Elena Guggiari, Francesca Lorentino, Simona Piemontese, Mara Morelli, Gabriele Antonarelli, Fabio Giglio, Serena Camilla Dalto, Sara Mastaglio, Elisa Sala, Francesca Pavesi, Matteo Giovanni Carrabba, Magda Marcatti, Sarah Marktel, Stefania Girlanda, Carlo Messina, Luca Vago, Francesca Lunghi, Massimo Bernardi, Consuelo Corti, Chiara Bonini, Jacopo Peccatori, Fabio Ciceri
Journal: Blood (2016)
Risk and health care costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer.
Authors: D. Weycker, J. Edelsberg, A. Kartashov, R. Barron, G. H. Lyman
Journal: Journal of Clinical Oncology (2011)

1050 Background: The burden of chemotherapy-induced neutropenic complications (CINC) in women with metastatic breast cancer (MBC) is largely unknown, and may differ across cancer populations due to variation in characteristics of patients, their disease, and their treatment. Methods: A retrospective cohort design and U.S. health care claims data (2003−2009) were employed to characterize risk and health care costs of CINC in women receiving taxane- or anthracycline-based regimens for MBC. For each woman, the first observed course, and each cycle and episode of CINC—if any—within the course, was characterized. CINC was identified via diagnosis codes for neutropenia, fever, or infection. Risk and health care costs—by care setting—were descriptively analyzed, on an overall basis, by cycle, and by regimen. Results: Among 2,620 study subjects, most received chemotherapy with cyclophosphamide/doxorubicin (25%), docetaxel (20%), or paclitaxel (12%). Thirty-one percent of subjects received colony-stimulating factors (CSF) prophylactically in their first chemotherapy cycle; an additional 13% first received CSF prophylaxis after cycle one. CINC developed in 11% of subjects; 88% required inpatient care and 45% experienced CINC in the first cycle. For CINC requiring inpatient care, costs averaged $12,869 (95% CI: $12,622−$13,116), and for CINC requiring outpatient care only, $2,030 ($1,925−$2,135). Conclusions:CINC is a clinically and economically important threat among women with MBC and should be an important consideration in the medical treatment of this patient population. Overall CYC/DOX DOC PAC (n=2,620) (n=641) (n=531) (n=316) Risk of CINC during course, % (95% CI) All events 11.0 (9.8-12.2) 9.7 (7.5-12.2) 11.5 (8.9-14.5) 7.6 (4.9-11.1) Requiring inpatient care 9.7 (8.6-10.9) 8.6 (6.5-11.0) 9.8 (7.4-12.6) 7.3 (4.7-10.7) Requiring outpatient care only 1.6 (1.2-2.2) 1.2 (0.5-2.4) 1.7 (0.8-3.2) 0.6 (0.1-2.3) Risk of CINC during cycle 1, % (95%CI) All events 4.9 (4.1-5.8) 3.7 (2.4-5.5) 4.1 (2.6-6.2) 2.8 (1.3-5.3) Requiring inpatient care 4.5 (3.7-5.3) 3.4 (2.2-5.2) 3.6 (2.2-5.5) 2.8 (1.3-5.3) Requiring outpatient care only 0.5 (0.2-0.8) 0.3 (0.0-1.1) 0.6 (0.1-1.6) 0.0 (0.0-1.2)
Long-Term Outcome and Prognostic Factors after Single-Unit Umbilical Cord-Blood Transplantation (UCBT) for Adults with Hematologic Malignancies.
Authors: Guillermo Sanz, Susana Cantero, Luis Larrea, Dolores Planelles, Ignacio Lorenzo, Barbara Banlloch, Luis Banlloch, Leonor Senent, Pau Montesinos, Jose Cervera, Carmen Jimenez, Guillermo Martin, Jesus Martinez, Isidro Jarque, Javier De la Rubia, Miguel A. Sanz
Journal: Blood (2006)
Tumor Marker CA 15-3 in Hematological Malignancies.
Authors: Zoi Saouli, Athanasios Papadopoulos, Georgia Kaiafa, Fotios Girtovitis, Georg Charisopoulos, Zisis Kontoninas, Anestis Zantidis, Charalambos Andreadis
Journal: Blood (2006)
JAK2 (V617F) Mutation Levels and Marrow Fibrosis in Patients Affected by Budd-Chiari Syndrome and Non-Cirrhotic Extra-Hepatic Portal Vein Obstruction.
Authors: Angela Rago, Chiara Marzano, Corrado Mammì, Carmelo Laganà, Angelo Fama, Luisa Bizzoni, Gabriella Tomei, Stefania Trasarti, Francesca Gioisa, Massimo Breccia, Ida Carmosino, Roberto Latagliata, Giuliana Alimena, Robert Foa, Oliviero Riggio, Agostino Tafuri
Journal: Blood (2007)
Quantitative analysis of IGF-1R expression in FFPE human rhabdomyosarcoma tumor tissue by mass spectrometry.
Authors: S. Malempati, T. A. Hembrough, S. Thyparambil, L. Cao, M. Darfler, D. Krizman, D. S. Hawkins, S. Skapek, L. J. Helman, J. Burrows
Journal: Journal of Clinical Oncology (2011)

10069 Background: The IGF-1R pathway is activated in many cancer types which has led to clinical development of many IGF1R targeted therapeutics. Multiple clinical trials targeting IGF1R are currently underway, however after initial optimism in NSCLC and Ewing’s sarcoma, several trials have failed to show efficacy or had severe toxicity. Pretreatment quantitation of tumor IGF1R protein expression remains a challenge due to high homology between IGF1R and the insulin receptor. Thus, there is a need for a specific and quantitative clinical assay for IGF1R protein expression. The ability to quantify IGF1R expression and determine signaling pathway activation status directly in formalin-fixed paraffin-embedded (FFPE) patient tissue biopsies should help identify patients most likely to benefit from anti-IGF1R therapies. Methods: We have developed a quantitative IGF1R assay which can be performed directly in FFPE patient tissue. This approach is based on the Liquid Tissue-SRM technology platform which enables relative and absolute quantification of proteins and their phosphorylation status directly in formalin fixed tissue. Results: The IGF1R-specific SRM assay was preclinically validated on cell lines expressing a range of IGF1R protein. The expression levels of IGF1R in seven formalin fixed rhabdomyosarcoma (RMS) cell lines were measured by SRM mass spectrometry. We detected a range of IGF1R expression from 68 to 333 amol/ug for these cell lines, values that showed extremely high correlation with antibody based techniques. Analysis of FFPE human rhabdomyosarcoma xenograft explants demonstrates that variable levels of IGF1R expression can be measured accurately. In xenografts where treatment with a therapeutic IGF1R antibody caused tumor regression there was a concomitant loss of IGF1R expression. We have extended these studies by characterizing the expression of IGF1R in a clinical cohort of ~40 RMS tumors. Conclusions: These novel techniques for quantifying protein expression in FFPE tissue enhance our ability to select patients for targeted therapy. Also, determining IGF1R expression in RMS tumor tissue is the first step to evaluating response to targeted therapy and IGF1R inhibition.
Does increasing number of core biopsies change the results of needle biospy in prostate cancer?
Authors: M. H. Farhat, A. Dabaja, P. Agarwal
Journal: Journal of Clinical Oncology (2011)

113 Background: The superiority of extended sampling of the prostate compared to standard sextant biopsy in predicting the final Gleason score has been controversial. In the literature, sextant biopsies have a match rate between 28–68% and an upgrading rate of 25–57%. Consequently, multiple studies recommend that extended biopsies should be the standard of care. This study examines the effect of greater core biopsy number on upgrading GS and predicting surgical pathology. Methods: Prostate biopsies of 984 patients who underwent RP between 2001 and 2008 were retrospectively reviewed. The GS of the biopsies was compared to the pathological specimens using the Chi-square test. Further adjusted comparison was performed using logistic regression. A clinical significant upgrade was defined as increase of the total GS or the primary GS. Results: The majority of the upgrading occurred in biopsy Gleason 3+3 and 3+4 cases. Upgrading was seen in 35.1% of patients with 6 cores or less, 34.5% with 7–12 cores, and 45.5% with 13+ cores (p=0.061). Number of cores, BMI, or prostate size did not affect upgrading, while perineural invasion, cancer volume on a biopsy, and D'Amico risk criteria increased the likelihood of upgrading. Conclusions: The extended core biopsy does not seem to correlate with higher gleason score or to better predict the final pathologic gleason score compared to standard sextant biopsies in prostate cancer. D'Amico risk factors, perineural invasion, and cancer volume can be viewed as risk factors for upgrading especially in GS 3+3. No significant financial relationships to disclose.
Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents
Authors: J. Christine Ye, Lakshminarayanan Nandagopal, Marie Ventimiglia, Muneer H. Abidi, Lois Ayash, Lawrence G Lum, Joseph P. Uberti, Voravit Ratanatharathorn, Jeffrey Zonder, Divaya Bhutani, Abhinav Deol
Journal: Blood (2014)
Mucocutaneous angiosarcoma (MC-AS) versus non-MC-AS: Clinicopathologic features and treatment outcomes in 44 patients (pts).
Authors: R. H. H. Quek, M. F. R. Harunal Rashid, W. S. Ong, M. J. F. Lee, R. Jeevan, Z. C. Ho, F. Chin, L. Soh, D. Poon, M. Teo
Journal: Journal of Clinical Oncology (2011)

10091 Background: Although the entity of MC-AS is well recognized, non MC-AS is less well reported and differences between the two are not well studied. We aimed to compare the clinical presentation and treatment outcomes of pts with MC-AS vs non MC-AS seen in our centre. Methods: Single centre retrospective study. Forty-four consecutive AS pts with complete medical records were identified from our sarcoma database. MC-AS is defined as AS arising from skin or superficial mucous membranes. Results: Median age of all pts was 69 yrs (range, 17-97 yrs), 59% were males, 2 pts had radiation-associated AS (both MC-AS); median follow-up was 8.9 mths. Thirty-four pts (77%) were classified as having MC-AS. Among the MC-AS subgroup, 88% of cases originated from the head and neck region; in the non MC-AS subgroup, 40% vs 20% vs 40% of cases originated from thoracic, abdominal organs and breast respectively. Compared with non MC-AS, median age of MC-AS pts was significantly higher (73 vs 42 yrs) (p<0.001) and more MC-AS pts were males (68% vs 30%) (p=0.064). Non MC-AS pts had significantly higher rates of metastatic disease at presentation (60% vs 15%) (p=0.008). Of 17 pts who underwent surgery as part of primary local control with known surgical margins, only 12% achieved microscopic negative margins, with no significant difference between the 2 groups. Sixteen patients with measurable disease received first line chemotherapy, 75% paclitaxel, achieved an overall response rate of 38% which did not differ significantly between the 2 groups. Median overall survival (OS) for the entire cohort was 10 mths, 9.5 mths vs 11.3 mths in pts with non MC-AS vs MC-AS respectively (p=0.894). Conclusions: Angiosarcoma is a rare disease with distinct clinical subsets and poor overall prognosis. Despite having a higher rate of metastatic disease at presentation, non MC-AS was not associated with a worse OS than MC-AS. This could be explained in part by the significantly older age at presentation of MC-AS potentially limiting use of aggressive multi-modality therapy in this pt population. These results also highlight the limitations of standard clinical staging tools in stratifying pts for survival within the MC-AS subgroup of pts.
A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease
Authors: George L. Chen, Paul A. Carpenter, Raewyn Broady, Tara B. Gregory, Sally Arai, Laura Johnston, Mary E.D. Flowers, Jan H. Beumer, Jodie Mendolsohn, Xin Zhou, Spenser H. Perloff, Joanne M Otani, David B Miklos
Journal: Blood (2011)
Preclinical Characterization of a Potent, Selective Inhibitor of the Protein Methyltransferase DOT1L for Use in the Treatment of MLL-Rearranged Leukemia.
Authors: Roy M Pollock, Scott R Daigle, Carly A Therkelsen, Aravind Basavapathruni, Lei Jin, Christina J Allain, Christine R Klaus, Alejandra Raimondi, Margaret Porter Scott, Richard Chesworth, Mikel P Moyer, Robert A Copeland, Victoria M Richon, Edward J Olhava
Journal: Blood (2012)
Rye bread consumption in early life and reduced risk of advanced prostate cancer.
Authors: Johanna Eyrun Torfadottir, Unnur Anna Valdimarsdottir, Lorelei Mucci, Meir J. Stampfer, Julie Kasperzyk, Katja Fall, Laufey Tryggvadottir, Thor Aspelund, Orn Olafsson, Tamara B. Harris, Eirikur Jonsson, Hrafn Tulinus, Hans-Olov Adami, Vilmundur Gudnason, Laufey Steingrimsdottir
Journal: Journal of Clinical Oncology (2012)

79 Background: Prior evidence suggests that rye consumption may reduce risk of prostate cancer (PCa). Our aim is to study whether consumption of rye bread and oatmeal (sources of lignans and fiber), both in early- and midlife, is associated with risk of PCa. Methods: In 2002 to 2006, 2,268 men, aged 67-96 years, reported their dietary habits in the AGES-Reykjavik cohort study. Dietary habits were assessed retrospectively, for early and midlife using a validated food frequency questionnaire (FFQ). Through linkage to cancer- and mortality registers, we retrieved information on PCa diagnosis and mortality through 2009. We used logistic regression to estimate odds ratios (ORs) for PCa according to rye- and oatmeal consumption, adjusted for possible confounding factors including fish-, fish liver oil-, meat-, and milk intake. Results: Of the 2268 men, 347 had or were diagnosed with PCa during follow-up, 63 with advanced disease (stage 3+ or died of PCa). Daily rye bread consumption in adolescence (vs. less than daily) was associated with a decreased risk of PCa diagnosis (OR 0.78; 95% CI: 0.60, 1.00), and of advanced PCa (OR 0.53; 95% CI: 0.32, 0.93). High intake of oatmeal in adolescence (≥5 vs. ≤4 times/ week) was not significantly associated with risk of PCa diagnosis (OR 1.00; 95% CI: 0.78, 1.29) nor advanced PCa (OR 0.73; 95% CI: 0.41, 1.31). Midlife consumption of rye or oatmeal was not associated with PCa risk. Conclusions: Our data suggest that frequent rye bread consumption in adolescence may be associated with reduced risk of PCa, particularly advanced disease.
Case 37-2016
Authors: Amir T. Fathi, Timothy A. Graubert, Naveen M. Kulkarni, Frank C. Kuo, Robert P. Hasserjian
Journal: New England Journal of Medicine (2016)

An 86-year-old woman was seen at this hospital because of fatigue, night sweats, leukocytosis, and splenomegaly. Review of the peripheral-blood smear revealed neutrophilia without dysplastic features, immature forms, or monocytosis. A diagnostic procedure was performed.
Two-Year Surveillance Study of Nosocomial Infections in Patients with Hematological Malignancies: Risk Factors for Antimicrobial Resistance and Their Impact in Mortality
Authors: Zoi Bousiou, Antonia Syrigou, Chrysavgi Lalayianni, Christos Smias, Ioanna Sakellari, Kyriaki Tsirou, Konstantinos Leontopoulos, Vasiliki Kalaitzidou, Eleni Tsorlini, Achilles Anagnostopoulos, Damianos Sotiropoulos
Journal: Blood (2016)
SOX11 Cooperates with CCND1 in Mantle Cell Lymphoma Pathogenesis
Authors: Pei-Yu Kuo, Zewei Jiang, Deepak Perumal, Violetta V Leshchenko, Alessandro Lagana', Samuel G. Katz, Loren D. Walensky, Rita Shaknovich, B. Hilda Ye, Samir Parekh
Journal: Blood (2015)
Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL
Authors: Jae H Park, Isabelle Riviere, Xiuyan Wang, Yvette Bernal, Terence Purdon, Elizabeth Halton, Yongzeng Wang, Kevin J. Curran, Craig S. Sauter, Michel Sadelain, Renier J. Brentjens
Journal: Blood (2015)
Intraoperative ultrasound for improvement of re-excision rates in breast-conserving surgery.
Authors: M. Knauer, P. Tschann, R. Koeberle-Wuehrer, U. Obwegeser, Z. Jasarevic, R. Stockinger, C. Hefel, A. Schuster, E. Wenzl, A. Haid
Journal: Journal of Clinical Oncology (2011)

91 Background: Due to improved screening for early breast cancer, the percentages of small and nonpalpable breast tumors have significantly increased during the last decades. After lumpectomy, re-excision rates of 32%-63% have been reported and the routine placement of localization needles is painful, time-consuming, and costly. In this study we investigated the value of intraoperative ultrasound (IOUS) in the hand of the breast surgeon as a fast and cheap method for potentially improving unacceptable re-excision rates. Methods: Between July 2001 and December 2010, in 773 of 1,195 breast cancer patients a breast-conserving treatment has been performed at the certified breast care center Vorarlberg (breast-conservation rate 64.7%). In 74.9% (579/773) of the tumors IOUS was performed, of which 44% were nonpalpable and 56% were insufficiently palpable, respectively. 7.5-10 MHz linear ultrasound probes were used by four breast surgeons in combination with intraoperative macroscopic resection margin assessment by the pathologist for prospective evaluation of definitive resection margin status over time. Furthermore, local recurrence rates were assessed. Results: During the study period, 579 of the included primary tumors were detected by IOUS. The metachronous re-excision rate was halved from 22% (30/135) in the period 2001-2003 to 11% (13/121) between 2008 and 2010. Between 2001 and 2010 we achieved a total re-excision rate of 13% (74/579). In 53% of re-excision specimens, no residual tumor was present, in 23% DCIS and in 24% invasive tumor was found, respectively. At a median follow-up of 56.4 months, a local recurrence rate of 1.7% was observed using our approach of IOUS combined with intraoperative margin assessment. Conclusions: IOUS in the hand of the breast surgeon proved to be a valuable, fast, and cheap method to improve metachronous re-excision rates in breast-conserving surgery. Patients can be spared the painful, costly, and time-consuming placement of a localization needle. Furthermore, tissue-sparing operations can be performed more easily and intraoperative specimen radiography can be avoided. The actual pathologic tumor size, however, is often being underestimated, especially regarding in situ cancers.
Postoperative complications from cytoreductive nephrectomy after neoadjuvant targeted therapy for metastatic renal cell carcinoma.
Authors: B. F. Chapin, S. E. Delacroix, S. H. Culp, G. Gonzalez, C. G. Wood
Journal: Journal of Clinical Oncology (2011)

300 Background: Neoadjuvant treatment of metastatic renal cell carcinoma (RCC) with targeted systemic therapies is under investigation. Postoperative complications that occurred after cytoreductive nephrectomy (CRN) preceded by neoadjuvant systemic therapy were assessed. Methods: A retrospective review of all patients with clinical evidence of metastasis that underwent CRN was performed. Of 683 surgical patients with metastatic disease, 67 had received preoperative targeted therapy. Preoperative, operative, and postoperative characteristics were evaluated for each patient. Surgical complications were assessed using the modified Clavien system. A multivariate was sued to determine preoperative variables in an attempt to predict surgical complications within 1 year of CRN. Results: Complications occurred in 64% (43/67) of patients within 365 days of CRN. Clavien grade ≥ 3 complications occurred in 30% (20/67) patients. The most common occurrences were superficial wound dehiscence (25%), and wound infection (15%). On univariate analysis there were no statistically significant differences between groups in regards to age, race, gender, smoking history, follow-up, Charlson comorbidity index, MSKCC risk groups, or time from cessation of targeted therapy to surgery. Significant predictors of complications included BMI ≥ 30 (p=0.007), EBL (p=0.019), matted nodes (p=0.043), and surgical approach (p=0.001). Clinical T-stage and N-stage (p=0.068, p=0.073) approached significance. On multivariate analysis Charlson comorbidity index ≥ 8(OR 5.2, 95% CI 1.23, 21.99) and clinical N-stage (OR 5.11, 95%CI 1.21, 21.66) were significant predictors of postoperative complications. Conclusions: In this series of patients treated with neoadjuvant targeted therapy, a majority of patients experienced a postoperative complication after CRN. A Charlson comorbidity index ≥ 8 or clinical node positivity predicted for an increased risk of postoperative complications. The use of neoadjuvant systemic targeted therapy prior to CRN is investigational and adequate assessment of operative morbidity is needed prior to wide spread adoption. No significant financial relationships to disclose.
Prolonged excretion of type-2 poliovirus from a primary immune deficient patient during the transition to a type-2 poliovirus-free world, Israel, 2016
Authors: Merav Weil, Lester M Shulman, Sophia Heiman, Tali Stauber, Jacqueline Alfandari, Leah Weiss, Ilana Silberstein, Viki Indenbaum, Ella Mendelson, Danit Sofer
Journal: Eurosurveillance (2016)

Wild poliovirus type-2 has been eradicated, use of live type-2 vaccine has been terminated globally, and all type-2 polioviruses are under strict laboratory containment protocols. Re-emergence may arise from prolonged asymptomatic excretion of poliovirus by hospitalised primary immune deficient (PID) patients, as described here, through repeated exposure of close contacts to high titres of infected material. At this transition time, PID patients should be screened and hospital containment protocols updated in parallel with laboratory containment.